Healthcare Stocks

PM Truss urged to put billions into social care

 PM Truss urged to put billions into social care

In her campaign, the PM had pledged to spend £13 billion on social care.

Read More...
Oxford Nanopore (ONT): What to expect after stellar listing?

Oxford Nanopore (ONT): What to expect after stellar listing?

UK based DNA sequencing biotechnology firm Oxford Nanopore Technologies PLC’s (LON: ONT) shares surged on listing on the LSE on Thursday, making it one of the best IPO debuts on the exchange. The company’s shares rose by over 45 per ce...

Read More...
Should you buy these pharma stocks with over 80% return in a year?

Should you buy these pharma stocks with over 80% return in a year?

Highlights  For the half-year ended 30 June 2021, Oxford Biomedica’s revenue increased by 139% year-on-year to £81.3 million compared to £34.0 million in H1 2020. Indivior Plc’s operating profit for Q2 2021 increase...

Read More...
MyHealthChecked (M3HC) & Alliance (APH): Are these pharma stocks a buy now?

MyHealthChecked (M3HC) & Alliance (APH): Are these pharma stocks a buy now?

Highlights  MyHealthChecked had recently acquired Nell Health Ltd, a technology-led genetic-testing platform and provider of personalised nutrition solutions, for £1.2 million. Alliance Pharma declared an interim dividend of 0.563 pe...

Read More...
AstraZeneca (LON: AZN) to acquire Caelum Biosciences: Buy alert?

AstraZeneca (LON: AZN) to acquire Caelum Biosciences: Buy alert?

Highlights Anglo-Swedish pharma company, AstraZeneca’s Alexion is set to acquire the remaining stake in rare disease biotech firm Caelum Biosciences. The deal is worth up to US$ 150 million, with a potential facility for making additional...

Read More...
Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

HIGHLIGHTS Saerum raised £2.37 million in June 2021 through two subscription contracts with high-net-worth individuals. In July 2021, the company received approval from the US Patent and Trademark Office for the use of SDC-1802 drug molec...

Read More...
Synairgen & Omega Diagnostics: 2 AIM pharma stocks for a healthy portfolio

Synairgen & Omega Diagnostics: 2 AIM pharma stocks for a healthy portfolio

Highlights  Omega Diagnostics filed for CE-mark on Covid-19 antigen self-test ‘Visitect’. Synairgen, last year generated £87.1 million to fund the SG018 Phase III trial. The exceptional pace of technological advancem...

Read More...
Open Orphan (ORPH) & Angle (AGL): 2 AIM pharma stocks to buy in September

Open Orphan (ORPH) & Angle (AGL): 2 AIM pharma stocks to buy in September

Pharma stocks listed on AIM present attractive investment opportunities for investors seeking to diversify their portfolios, and they simultaneously offer ample growth prospects. AIM pharma stocks comprise smaller pharmaceutical companies that desi...

Read More...
UK may offer Covid-19 jabs to 12- 15-year-olds. Stocks to look at

UK may offer Covid-19 jabs to 12- 15-year-olds. Stocks to look at

Highlights  NHS England to prepare for a potential extension of the Covid vaccination programme to all 12 to 15-year-olds from early September. No advice regarding vaccine rollout provided by JCVI yet, but forward planning to be started. ...

Read More...
Faron (LON: FARN) & Novacyt (LON: NCYT) shares. Should you buy them now?

Faron (LON: FARN) & Novacyt (LON: NCYT) shares. Should you buy them now?

Highlights  Faron Pharmaceuticals Oy share prices suffered a sharp correction of around 7 per cent. For the H1 2021 ended 30 June 2021, Novacyt recorded revenues of £94.7 million, up by over 50% compared to £63.3 million in H1 ...

Read More...
Inspira supports Vectura’s (LON: VEC) £1.1bn acquisition by Philip Morris

Inspira supports Vectura’s (LON: VEC) £1.1bn acquisition by Philip Morris

Highlights  Inspira Pharmaceuticals comes out to support Vecutra’s £1.1 billion takeover by US-based Philip Morris International amid rising criticism due to potential threats to the UN’s sustainability goals and future co...

Read More...